B · Normal
[Hengrui Medicine: Revelutamide Tablets Received Clinical Trial Approval Notice] On October 22, Hengrui Medicine (600276.SH) announced that the company received the approval from the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for revelutamide tablets and agreed to conduct Phase III clinical research on prostate cancer. Revelutamide tablets are a second-generation AR inhibitor. The company's drug has been approved for marketing in 2022 for the treatment of patients with metastatic hormone-sensitive prostate cancer with high tumor burden. Up to now, the cumulative R&D investment in projects related to revelutamide tablets has been approximately 740 million yuan.
A-share announcement express 🕐 2026-10-22 17:03
#clinical trial #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Chinatungsten High-tech: Subsidiary Zhuzhou Hard Alloy Company plans to invest 10-22 18:14 [Chinatungsten High-tech: Net profit in the third quarter increased by 149% year 10-22 18:14 [Han's Laser: Net profit in the third quarter increased by 137% year-on-year] On 10-22 18:09 [Zhenan Technology: Planning to acquire no less than 51% of the equity of Shenzh 10-22 18:03 [Daqian Eco: Plans to change securities abbreviation to Lingdong Shares] On Octo 10-22 17:56 [Shengyi Electronics: Repurchased 285,400 shares for the first time on October 2 10-22 17:42

Comments

0/500
Captcha (click to refresh)
No comments yet